In development“We remain committed to our mission to evaluate phage-based therapeutics in randomized controlled clinical trials that evaluate safety and efficacy required to support potential regulatory approval and commercialization of our phage products as alternatives to traditional antibiotics, providing a potential method of treating patients suffering from drug-resistant and difficult-to-treat bacterial infections.”
Convertible-loan fair-value losses drove the net loss; Innoviva credit maturities were extended amid a going-concern warning.
Latest 8-KDebt financingGovernance change ·
Innoviva subsidiary extends credit maturities and warrant expirations; FDA approval of a product candidate now triggers early termination of the voting agreement.
Sells it“Our Genotype and Fluorotype molecular diagnostics (“MDx”) kits enable a culture-free detection and analysis of microbes and viruses directly from patient samples with a special focus on tuberculosis, HIV viral load, viral hepatitis and sexually transmitted diseases.”
Weak BioSpin and NANO demand, tariffs and impairments overwhelmed CALID growth; Bruker is restructuring to restore margins.
Revenue$3.4BYoY +2.1%
Net income−$8.6Mvs $113.1M year ago
Latest 10-QQ3 FY2026Impairment / charge ·
Competition and weak BSB&CA performance erase its remaining goodwill, while cost savings and product mix lift margins.
Revenue$874.0MYoY +1.6%
Net income−$111.8MYoY −87.6%
Latest 8-KLeadership change ·
Board adds immunologist Eicke Latz as life-science work expands; declares $0.05/share quarterly dividend.
Latest 8-KInvestor update ·
BioSpin and CALID divisions reorganized into BIOS and new BMID to sharpen accountability; historical segment results recast without changing consolidated results.
Sells it 24%, $98.5M a year“Our wholly owned, robust critical care and infectious disease operating platform with a hospital focus, is anchored by five differentiated approved, commercial and marketed products:”
Latest 10-KFY2025Positive ·
GIAPREZA and XACDURO lifted product sales, but at-cost Zai Lab supply limited margins; Armata investment gains drove GAAP earnings.
Revenue$411.3MYoY +14.7%
Net income$271.2Mvs $23.4M year ago
Latest 10-QQ3 FY2026Positive ·
XACDURO and GIAPREZA lift U.S. hospital sales; Armata markdowns overwhelm stronger operating earnings
Revenue$106.1MYoY −1.6%
Net income−$73.9Mvs $89.9M year ago
Latest 8-KEarningsGuidance reaffirmed ·
Lower royalties and ex-U.S. sales timing weighed on revenue; $139.5M in investment markdowns, mainly Armata, drove the net loss.
Latest 8-KLeadership change ·
Derek Small and Mark DiPaolo resign from the board to grow Syndeio BioSciences; Josephine Linden joins.
Latest 8-KShareholder voteExecutive pay ·
Stockholders approved the 2026 Equity Incentive Plan and elected five directors to one-year terms.
European COVID deliveries and lower R&D spending restored quarterly profit; mFLUSIVA launched after the main contracting season.
Revenue$1.3BYoY +29.2%
Net income$162.0Mvs −$200.0M year ago
Latest 8-KPositiveDebt financing ·
Credit amendment cuts initial and delayed-draw term-loan margins 75 bp and extends maturity to November 2031.
Latest 8-KLeadership change ·
Chief Legal Officer Klinger to retire March 2027 with $1.63M severance and conditional payouts tied to Arbutus/Genevant and Pfizer/BioNTech litigation.
Sells it“Our R&D primarily focuses on our main therapeutic areas, which are oncology, internal medicine (including cardiometabolic, weight management and migraine), vaccines (with a pipeline focus on infectious diseases with significant unmet medical need) and inflammation and immunology.”
Latest 10-KFY2025Impairment / charge ·
Paxlovid and Comirnaty declines masked non-COVID growth; the Metsera deal targets obesity as patent losses loom.
Revenue$62.6BYoY −1.6%
Net income$7.8BYoY −3.2%
Latest 10-QQ3 FY2026MixedImpairment / charge ·
Eliquis and Padcev gains counter COVID-19 declines, but pipeline write-downs expose risks in replacing aging franchises.
Revenue$16.6BYoY −0.4%
Net income$3.2BYoY −8.4%
Latest 8-KCEO/CFO change ·
Interim CFO Cecile Guegan appointed permanent CFO and EVP, effective Nov. 1.
Supplies it“We have entered into drug discovery collaborations with biopharmaceutical companies under which our collaborators are pursuing research in a number of therapeutic areas, including programs in oncology, antifungal diseases, fibrosis, inflammatory bowel disease, metabolic disease, autoimmune disease, immuno-oncology, cardiopulmonary disease, CNS diseases, and tuberculosis.”
Latest 10-KFY2025MixedRestructuring ·
Novartis collaboration work and hosted-software sales drove growth, but higher delivery costs squeezed gross margin.